East India Pharmaceutical Works Limited (EIPWL) is one of India’s oldest pharmaceutical companies, with a legacy dating back to 1936. Headquartered in Kolkata, West Bengal, the company is engaged in the manufacturing and marketing of pharmaceutical formulations and bulk drugs. It operates in the healthcare and pharmaceutical sector and remains an unlisted public company.
Over the decades, EIPWL has developed a diversified portfolio across therapeutic and healthcare categories, including analgesics, antibiotics, hematinics, vitamins, gastrointestinal medicines and Ayurvedic formulations. Its well-known brands include Pyrigesic, Locula, Tonoferon, Vitazyme and Enteroquinol, among others.
The company has manufacturing operations in Sarsuna, Kolkata and Durgapur, West Bengal. Its facilities support pharmaceutical formulation manufacturing as well as API production, with the company highlighting WHO-GMP-compliant manufacturing capabilities.
Business & Product Portfolio
East India Pharmaceutical Works operates across:
Pharmaceutical formulations
Bulk drugs / APIs
Tablets and capsules
Dry syrups and liquid formulations
Ointments and topical products
Vitamins and hematinics
Analgesic and antipyretic medicines
Gastrointestinal medicines
Antibiotic and anti-infective formulations
Ayurvedic and healthcare products
The company has historically invested in research and development and has built a nationwide distribution presence for its products.
Manufacturing & R&D
EIPWL's manufacturing infrastructure includes a formulation facility at Sarsuna and an API/synthetic drugs facility at Durgapur. Its operations cover manufacturing, quality control, research and development and pharmaceutical packaging.
The company states that its focus is on developing quality and affordable medicines while continuing to strengthen its R&D and healthcare capabilities.
Financial Performance
According to the financial data presented on the UnlistedZone reference page, revenue increased from approximately ₹234 Cr in FY23 to ₹250 Cr in FY24 and ₹272 Cr in FY25. However, profitability was comparatively weaker, with PAT moving from ₹3.8 Cr in FY24 to approximately ₹2 Cr in FY25.
The FY25 annual report describes the company as an established pharmaceutical manufacturer with WHO-GMP-compliant facilities and a portfolio spanning multiple therapeutic categories.
This combination of revenue growth and relatively modest profitability makes margin performance, operating efficiency and sustainable earnings growth important factors for investors to monitor.
Shareholding & Corporate Information
As of FY25, the reference data shows approximately 25.87% promoter holding and 74.13% holding under others. The company has an authorised share capital of ₹10 Cr and paid-up capital of approximately ₹6.67 Cr.
Company: East India Pharmaceutical Works Limited
Incorporated: 27 April 1936
CIN: U24231WB1936PLC008598
ISIN: INE254X01017
Registered Office: Kolkata, West Bengal
Face Value: ₹10 per share
Listing Status: Unlisted
Paid-up Capital: ~₹6.67 Cr
Promoter Holding: 25.87% as of FY25
East India Pharmaceutical Works Unlisted Shares
Since East India Pharmaceutical Works Limited is not listed on NSE or BSE, its shares do not have a continuously traded exchange price. Indicative prices available through unlisted-share platforms can vary depending on transaction demand, available supply, valuation expectations and market conditions.
The historical reference page from UnlistedZone displays ₹79 as an indicative price dated 3 November 2021, while other current data sources show different indicative levels. Therefore, any price displayed on an unlisted-share page should be treated as indicative and subject to confirmation, rather than as a guaranteed executable price.
Why Investors Track East India Pharmaceutical Works
Some factors that may attract investor interest include:
Nearly nine decades of operating history
Established pharmaceutical manufacturing capabilities
Diversified product portfolio
Presence across formulations and APIs
Recognised legacy brands
WHO-GMP-compliant manufacturing capabilities
Established distribution network
Exposure to India's long-term healthcare and pharmaceutical demand
At the same time, investors should evaluate profitability, working capital requirements, debt, valuation, liquidity and the absence of an exchange-listed market before considering an investment.
Key Risks to Consider
Investment in unlisted shares carries additional risks compared with listed securities. For East India Pharmaceutical Works, investors should particularly evaluate:
Limited liquidity in unlisted shares
Indicative price volatility
Pharmaceutical regulatory and compliance requirements
Competition within the pharmaceutical industry
Raw-material and manufacturing costs
Margin pressure
Working-capital requirements
Execution and business-performance risks
Limited public-market price discovery
Uncertainty regarding any future IPO or listing
There is no guarantee that East India Pharmaceutical Works will list its shares on a stock exchange or that an investor will realise a profit.
Explore East India Pharmaceutical Works Limited Unlisted Shares with Dhankirti and conduct your own due diligence before making an investment decision.
